DaVita Inc. (NYSE:DVA) Shares Sold by Ritholtz Wealth Management

Ritholtz Wealth Management lessened its position in DaVita Inc. (NYSE:DVA) by 23.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,537 shares of the company’s stock after selling 2,246 shares during the period. Ritholtz Wealth Management’s holdings in DaVita were worth $1,236,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of DVA. Vanguard Group Inc. increased its stake in shares of DaVita by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock valued at $662,161,000 after purchasing an additional 145,711 shares during the period. Harvard Management Co. Inc. acquired a new position in shares of DaVita during the second quarter valued at approximately $55,115,000. Lazard Asset Management LLC raised its holdings in DaVita by 147.3% during the first quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after purchasing an additional 153,008 shares in the last quarter. Andra AP fonden lifted its position in DaVita by 9.0% in the second quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after purchasing an additional 15,800 shares during the period. Finally, Jupiter Asset Management Ltd. boosted its stake in DaVita by 146.7% during the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock valued at $25,840,000 after purchasing an additional 111,311 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock worth $27,387,069 over the last quarter. Corporate insiders own 2.00% of the company’s stock.

DaVita Trading Up 0.9 %

Shares of DVA opened at $160.85 on Monday. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 1-year low of $71.84 and a 1-year high of $166.04. The stock has a market capitalization of $14.11 billion, a P/E ratio of 18.28, a P/E/G ratio of 0.91 and a beta of 0.87. The business’s 50-day moving average price is $154.19 and its 200 day moving average price is $143.78.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. During the same quarter in the previous year, the business earned $2.08 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. Analysts expect that DaVita Inc. will post 9.99 earnings per share for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of research reports. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $159.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.